BFM
TBPH icon

Boothbay Fund Management’s Theravance Biopharma TBPH Stock Holding History

Boothbay Fund Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-35,477
Closed -$360K – 2435
2022
Q3 		$360K Buy
+35,477
New +$332K 0.01% 1414
2018
Q4 		– Sell
-21,132
Closed -$690K – 886
2018
Q3 		$690K Buy
+21,132
New +$576K 0.07% 281

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Boothbay Fund Management's TBPH Position: Q4 2022 in Review

Boothbay Fund Management sold out of Theravance Biopharma (TBPH) in Q4 2022, closing a stake of 35,477 shares — an estimated $360K sold.

Boothbay Fund Management first reported a position in TBPH in Q3 2018 and held it in 2 quarters. The position peaked at $690K in Q3 2018. 119 funds tracked by Wall St. Rank hold TBPH as of Q4 2022.

  • Boothbay Fund Management reported no remaining Theravance Biopharma position as of Q4 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 35,477 Theravance Biopharma shares in Q4 2022, an estimated $360K.
  • Boothbay Fund Management first reported a position in Theravance Biopharma in Q3 2018 and held it in 2 quarters.
  • Boothbay Fund Management's Theravance Biopharma position peaked at $690K in Q3 2018.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2022.

Based on Boothbay Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.